The most active compounds 17, 23, 25 and 27 were tested in vitro in DU145, an androgen insensitive prostate cancer cell line (PCa) with very low or undetectable AR levels, which represents the castration-resistant PCa (CRPC) model. Here, AR is linked to prostate carcinoma.